News from cardiovascularbusiness.comFollowNews from cardiovascularbusiness.comAll of today’s top news stories from cardiovascularbusiness.com. Get the full analysis behind how media bias impacts breaking news.We’ve aggregated 140 of cardiovascularbusiness.com’s headlines and news stories over the past 3 months. cardiovascularbusiness.com’s media bias is . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. Is cardiovascularbusiness.com credible or reliable? Our Factuality score answers both of those questions. When it comes to cardiovascularbusiness.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.Follow All of today’s top news stories from cardiovascularbusiness.com. Get the full analysis behind how media bias impacts breaking news. We’ve aggregated 140 of cardiovascularbusiness.com’s headlines and news stories over the past 3 months. cardiovascularbusiness.com’s media bias is . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. Is cardiovascularbusiness.com credible or reliable? Our Factuality score answers both of those questions. When it comes to cardiovascularbusiness.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check. Information about cardiovascularbusiness.comWhere is cardiovascularbusiness.com located?cardiovascularbusiness.com's WebsiteMedia Bias RatingsDo you diasgree? Edit biasLearn more about Media Bias Ratings.FactualityAverage Factuality Rating: UnknownLearn more about Factuality Ratings.Top cardiovascularbusiness.com NewsFDABridgeBio heart drug approved by FDA, setting up battle with Pfizer67% Center coverage: 3 sourcesThe approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market that investors have been skeptical BridgeBio can win.See the StoryArtificial Intelligence · United StatesFDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis DetectionThe AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.See the StoryMaryland · MarylandNew ATTR-CM drug linked to positive long-term data as FDA nears final decisionDaniel Judge, MD, discussed late-breaking data on acoramidis, a new drug therapy for transthyretin amyloid cardiomyopathy. A final decision from the FDA on acoramidis is expected in the days ahead.See the StoryLatest News StoriesTopics Most Covered by cardiovascularbusiness.comMedicareArtificial IntelligenceHealthDiabetesSoftwareMedicareArtificial IntelligenceHealthSources Covering Similar TopicsMedical Device Networkdiagnosticimaging.commedtechdive.comMedPage Todayhitconsultant.netMedical Device Networkdiagnosticimaging.commedtechdive.comSuggest a sourceLooking for a source we don't already have? Suggest one here.You've scrolled to the bottom of the feed, there are no more stories.
